| pubmed-article:9058517 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9058517 | lifeskim:mentions | umls-concept:C0007112 | lld:lifeskim |
| pubmed-article:9058517 | lifeskim:mentions | umls-concept:C0006098 | lld:lifeskim |
| pubmed-article:9058517 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:9058517 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:9058517 | lifeskim:mentions | umls-concept:C1521828 | lld:lifeskim |
| pubmed-article:9058517 | lifeskim:mentions | umls-concept:C0392752 | lld:lifeskim |
| pubmed-article:9058517 | lifeskim:mentions | umls-concept:C1511253 | lld:lifeskim |
| pubmed-article:9058517 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9058517 | pubmed:dateCreated | 1997-5-9 | lld:pubmed |
| pubmed-article:9058517 | pubmed:abstractText | From September 1989 to February 1993, 11 patients with localized adenocarcinoma of the prostate were treated with pelvic external-beam radiation therapy followed by high dose rate (HDR) transurethral brachytherapy as a boost dose. External-beam radiation therapy was administered through opposed pelvic fields using a 60Co teletherapy unit to a tumor dose of 46-50 Gy in 23-25 fractions and followed by three fractions of transurethral brachytherapy, delivered using a 60Co HDR remote afterloading equipment. The treatment time was calculated using the prostatic capsule as the reference point. The dose calculated to be delivered to the capsule was 5 Gy/fraction, making a total of 15 Gy. The follow-up period ranged from 11 to 65 months, with a median follow-up time of 30 months. Local control was achieved in all patients. The prostate-specific antigen levels were normalized within 3 months of radiotherapy in 9 patients and within 3-6 months in the remaining 2. Transurethral brachytherapy appears to be a simple and feasible form of brachytherapy. Preliminary local control and radiotherapy-related morbidity rates are comparable to those of other forms of brachytherapy. Further follow-up is required for assessment of long-term local control and delayed radiotherapy-related morbidity. | lld:pubmed |
| pubmed-article:9058517 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9058517 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9058517 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9058517 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9058517 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9058517 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9058517 | pubmed:issn | 0042-1138 | lld:pubmed |
| pubmed-article:9058517 | pubmed:author | pubmed-author:CakmakAA | lld:pubmed |
| pubmed-article:9058517 | pubmed:author | pubmed-author:SaxS MSM | lld:pubmed |
| pubmed-article:9058517 | pubmed:author | pubmed-author:AkkayaAA | lld:pubmed |
| pubmed-article:9058517 | pubmed:author | pubmed-author:Gö?ü?OO | lld:pubmed |
| pubmed-article:9058517 | pubmed:author | pubmed-author:SerinMM | lld:pubmed |
| pubmed-article:9058517 | pubmed:author | pubmed-author:ErkalH SHS | lld:pubmed |
| pubmed-article:9058517 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9058517 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:9058517 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9058517 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9058517 | pubmed:pagination | 30-3 | lld:pubmed |
| pubmed-article:9058517 | pubmed:dateRevised | 2006-10-30 | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:meshHeading | pubmed-meshheading:9058517-... | lld:pubmed |
| pubmed-article:9058517 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9058517 | pubmed:articleTitle | High dose rate transurethral brachytherapy as a boost dose for localized adenocarcinoma of the prostate. | lld:pubmed |
| pubmed-article:9058517 | pubmed:affiliation | Department of Radiation Oncology, Ankara University Faculty of Medicine, Turkey. | lld:pubmed |
| pubmed-article:9058517 | pubmed:publicationType | Journal Article | lld:pubmed |
